JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on December 13, 2002; DOI: 10.1124/jpet.102.045005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.102.045005v1
304/3/1181    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sandoval, V.
Right arrow Articles by Fleckenstein, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sandoval, V.
Right arrow Articles by Fleckenstein, A. E.

Vol. 304, Issue 3, 1181-1187, March 2003

Methylphenidate Alters Vesicular Monoamine Transport and Prevents Methamphetamine-Induced Dopaminergic Deficits

Verónica Sandoval, Evan L. Riddle, Glen R. Hanson and Annette E. Fleckenstein

Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah

It has been hypothesized that high-dose methamphetamine treatment rapidly redistributes cytoplasmic dopamine within nerve terminals, leading to intraneuronal reactive oxygen species formation and well characterized persistent dopamine deficits. We and others have reported that in addition to this persistent damage, methamphetamine treatment rapidly decreases vesicular dopamine uptake, as assessed in purified vesicles prepared from treated rats; a phenomenon that may contribute to aberrant intraneuronal dopamine redistribution proposedly caused by the stimulant. Interestingly, post-treatment with dopamine transporter inhibitors protect against the persistent dopamine deficits caused by methamphetamine; however, mechanisms underlying this phenomenon have not been elucidated. Also of interest are findings that dopamine transporter inhibitors, including methylphenidate, rapidly increase 1) vesicular dopamine uptake, 2) vesicular monoamine transporter-2 (VMAT-2) ligand binding, and 3) VMAT-2 immunoreactivity in a vesicular subcellular fraction prepared from treated rats. Therefore, we hypothesized that methylphenidate post-treatment might protect against the persistent striatal dopamine deficits caused by methamphetamine by rapidly affecting VMAT-2 and vesicular dopamine content. Results reveal that methylphenidate post-treatment both prevents the persistent dopamine deficits and reverses the acute decreases in vesicular dopamine uptake and VMAT-2 ligand binding caused by methamphetamine treatment. In addition, methylphenidate post-treatment reverses the acute decreases in vesicular dopamine content caused by methamphetamine treatment. Taken together, these findings suggest that methylphenidate prevents persistent methamphetamine-induced dopamine deficits by redistributing vesicles and the associated VMAT-2 protein and presumably affecting dopamine sequestration. These findings not only provide insight into the neurotoxic effects of methamphetamine but also mechanisms underlying dopamine neurodegenerative disorders, including Parkinson's disease.

0022-3565/03/3043-1181$07.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
S. J. Farnsworth, T. J. Volz, G. R. Hanson, and A. E. Fleckenstein
Cocaine Alters Vesicular Dopamine Sequestration and Potassium-Stimulated Dopamine Release: The Role of D2 Receptor Activation
J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 807 - 812.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. J. Volz, S. J. Farnsworth, S. D. Rowley, G. R. Hanson, and A. E. Fleckenstein
Methylphenidate-Induced Increases in Vesicular Dopamine Sequestration and Dopamine Release in the Striatum: The Role of Muscarinic and Dopamine D2 Receptors
J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 161 - 167.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. J. Volz, S. J. Farnsworth, J. L. King, E. L. Riddle, G. R. Hanson, and A. E. Fleckenstein
Methylphenidate Administration Alters Vesicular Monoamine Transporter-2 Function in Cytoplasmic and Membrane-Associated Vesicles
J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 738 - 745.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. S. Rau, E. Birdsall, T. J. Volz, J. A. Riordan, A. J. Baucum II, B. P. Adair, R. Bitter, J. W. Gibb, G. R. Hanson, and A. E. Fleckenstein
Methamphetamine Administration Reduces Hippocampal Vesicular Monoamine Transporter-2 Uptake
J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 676 - 682.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
P. R Padala, F. Petty, and S. C Bhatia
Methylphenidate May Treat Apathy Independent of Depression
Ann. Pharmacother., November 1, 2005; 39(11): 1947 - 1949.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. G. Truong, D. G. Wilkins, J. Baudys, D. J. Crouch, K. L. Johnson-Davis, J. W. Gibb, G. R. Hanson, and A. E. Fleckenstein
Age-Dependent Methamphetamine-Induced Alterations in Vesicular Monoamine Transporter-2 Function: Implications for Neurotoxicity
J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1087 - 1092.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. J. Eyerman and B. K. Yamamoto
Lobeline Attenuates Methamphetamine-Induced Changes in Vesicular Monoamine Transporter 2 Immunoreactivity and Monoamine Depletions in the Striatum
J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 160 - 169.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. L. Johnson-Davis, J. G. Truong, A. E. Fleckenstein, and D. G. Wilkins
Alterations in Vesicular Dopamine Uptake Contribute to Tolerance to the Neurotoxic Effects of Methamphetamine
J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 578 - 586.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.